Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of TRTL-913 in healthy adults and adults with tinnitus. The study has two parts Part A is a double-blind phase assessing 7 days of dosing in healthy volunteers to understand how the drug behaves in the body and its safety profile. Part B is an open-label phase evaluating a 2-week treatment course in adults with tinnitus to assess safety and potential benefits. Participants in Part A will be randomly assigned to receive either TRTL-913 capsules or a matching placebo once daily for 7 days. In Part B, participants with tinnitus will self-administer TRTL-913 capsules once daily for 14 days, with dosing possibly adjusted based on Part A results. The study uses a parallel design and includes careful monitoring throughout both parts. During the study, participants will undergo safety assessments including vital signs, laboratory tests, ECGs, and monitoring for adverse events. For Part B, researchers will measure changes in tinnitus severity using standard tools like the Tinnitus Functional Index and Tinnitus Handicap Inventory over 21 days. The study will also assess plasma concentrations of TRTL-913 in Part A. Participants are closely monitored for any signs of suicidal thoughts or behavior. The total study duration varies depending on the part but involves up to 21 days of observation.
Actively Recruiting
Researchers are evaluating Ratutrelvir 83-0060, a drug that inhibits the main protease of SARS-CoV-2, along with Paxlovid Nirmatrelvir plus Ritonavir, to understand their safety and effectiveness in adults with mild to moderate COVID-19 who are not hospitalized. This open-label, randomized Phase 2a study aims to determine a safe and effective dose of Ratutrelvir and compare it with standard care, providing important information on how these treatments may help manage COVID-19 symptoms and recovery. Participants will be assigned to receive either Ratutrelvir or Paxlovid alongside standard care. The study is multicenter and open-label, meaning both researchers and participants know which treatment is given. The trial includes an experimental group receiving Ratutrelvir, a comparator group receiving Paxlovid, and a non-randomized group receiving Ratutrelvir. Treatment is given during the study period, and the research team monitors the drugs concentration in the blood to understand how it behaves in the body. During the 28-day study period, participants will be closely monitored for safety based on the occurrence and severity of any adverse events. The team will assess how long it takes for COVID-19 symptoms to improve and recover fully. Blood samples will be collected up to day 11 to analyze drug levels. Participants will undergo symptom evaluations regularly, and their health will be tracked throughout the study to ensure safety and gather data on treatment effects.
Actively Recruiting
Researchers are studying the safety of BHV-1300 as a treatment for adults with Graves Disease. This Phase 1 trial aims to explore how BHV-1300 affects biomarkers related to this condition to better understand its impact. The study is led by Biohaven Therapeutics Ltd. and focuses on monitoring the treatments safety profile over time. Participants will receive BHV-1300, which is given as a subcutaneous injection. This open-label study does not include placebo control or blinding, and all participants receive the same treatment. The treatment period and follow-up extend up to 52 weeks to observe effects and any adverse events. During the study, participants will be closely monitored for serious adverse events, side effects that may lead to stopping treatment, and laboratory abnormalities. Researchers will regularly assess health status and collect data on disease-specific biomarkers. The total duration of participation is approximately one year, ensuring comprehensive safety and effect evaluations.